I disagree. From the time of the CRL, MSB has been aiming for a conditional approval -- condition being trial in adults. Conditional approval will facilitate funding and expedite recruitment for that trial and, if successful, label extension. Be careful, because the shorts are deliberately promoting the idea that conditional approval will be a negative, whereas it will in fact be what the company has been striving for since the CRL.
2023 The Final Countdown, page-3136
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |